EnPlusOne Biosciences, a biotechnology company utilizing the power of enzymes to deliver better RNA at scale, announced that it had raised additional funding to scale and drive continued technical advancements of its ezRNA synthesis platform.
The funding round of about $10 million, was led by Northpond Ventures and Breakout Ventures, highlighting their ongoing support and enthusiasm for the company’s progress. And it is another key milestone along the company’s development and commercialization roadmap, in line with its mission to enable next-generation solutions for emerging RNA therapeutics.
As part of this increased investment, Julia Moore, Managing Partner at Breakout Ventures, will join the EnPlusOne Board of Directors. Moore has been a Board Observer since the company’s formation.
EnPlusOne is a team of chemists, biologists, and engineers to bring RNA of limitless scale and design to reality. And their ezRNA platform is a novel, template-free, aqueous-based, and enzymatic RNA synthesis technology providing new approaches to manufacturing RNA therapeutics. And recent commercial success and pipeline growth in RNAi, mRNA, and gene editing therapeutics are driving a rapid increase in RNA demand. Utilizing the ezRNA platform, EnPlusOne is poised to solve the siRNA scale problem, the gRNA purity problem, and expand RNA design for novel therapeutics with enabling modifications.
These are some of the company’s recent highlights:
— Published foundational technology in Nature Bio
— Synthesized the antisense strand of Leqvio (inclisiran)
— Awarded ARPA-H Contract ($27 million collaboration led by Wyss Institute)
— Met with partners and customers at the JP Morgan Healthcare conference in January
EnPlusOne will present at the upcoming TIDES Asia conference in Singapore in late February and the TIDES USA conference in San Diego in late May.
KEY QUOTES:
“The EnPlusOne team has made significant progress in advancing enzymatic RNA synthesis, positioning its platform as a foundational engine for the future of high-quality RNA manufacturing. We are excited about the potential of this technology to transform the field and look forward to supporting the team as they move toward full-scale commercialization.”
- Paxton Major, Managing Director, Northpond Ventures
“We highly value the confidence of our investors as our team works to optimize, scale, and advance our ezRNA platform. Our goal is ambitious: scaling our siRNA platform and accelerating recent technical progress in the synthesis of high-purity guide RNA for gene editing. We expect several key announcements this year as we move closer to achieving this goal. The RNA therapeutics space remains vibrant and ever evolving, and we see the ezRNA platform as a key enabler in this field. We are focused on increasing awareness of the unique and important advantages our technology provides and look forward to collaborating with developers on the cutting edge of RNA science.”
- Dan Ahlstedt, Co-founder, COO, and Board Director of EnPlusOne Bio
